AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
With cancer rising in women under 40, there's concern about the causes — and the effects. PEOPLE's editor-in-chief Charlotte ...
16hon MSN
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...
Researchers at Fred Hutch Cancer Center have discovered an overlooked mechanism driving aggressive breast and brain tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results